{"title":"Analysis: Study design contributed to differences in ketamine-ECT trials","authors":"","doi":"10.1002/pu.31162","DOIUrl":null,"url":null,"abstract":"<p>Differences in study population characteristics and treatment modalities were largely responsible for the discordant findings between the two adequately powered trials that have compared ketamine treatment and electroconvulsive therapy (ECT) for major depressive disorder, an analysis has concluded. Remission rates with ECT treatment diverged significantly, at 63% in one of the studies and 22% in the other. Results of the analysis were published online Dec. 19, 2023 in the <i>International Journal of Neuropsychopharmacology</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Differences in study population characteristics and treatment modalities were largely responsible for the discordant findings between the two adequately powered trials that have compared ketamine treatment and electroconvulsive therapy (ECT) for major depressive disorder, an analysis has concluded. Remission rates with ECT treatment diverged significantly, at 63% in one of the studies and 22% in the other. Results of the analysis were published online Dec. 19, 2023 in the International Journal of Neuropsychopharmacology.
一项分析得出结论说,研究人群特征和治疗方式的差异在很大程度上导致了两项有充分证据支持的试验结果不一致,这两项试验对氯胺酮治疗和电休克疗法(ECT)治疗重度抑郁症进行了比较。ECT治疗的缓解率差异很大,其中一项研究的缓解率为63%,另一项研究的缓解率为22%。分析结果于2023年12月19日在线发表在《国际神经精神药理学杂志》(International Journal of Neuropsychopharmacology)上。